Mar 17, 2022 / 02:00PM GMT
Hartaj Singh - Oppenheimer & Co. Inc., Research Division - Research Analyst
Great. Thank you, Brad. Thanks for getting us going here. Hey, everybody. Welcome this morning to the third day of the Oppenheimer Healthcare Conference. My name is Hartaj Singh. I'm one of the biotechnology analysts over here. And it's a real pleasure to have one of the most innovative companies on the planet, in my opinion, with us today, the CFO, David Meline; and Lavina Talukdar, I still can't say it. Sorry, I'm just spelling names, but I have both of you here. We'll get going with David doing a quick presentation and then go to our fireside chat.
So David, please take it away.
David W. Meline - Moderna, Inc. - CFO & Principal Accounting Officer
Yes. Thank you very much, and good morning, afternoon to all. So what I'll do is just cover briefly '21, '22 and events that have occurred more recently since our last quarterly call.
So in terms of 2021, we delivered during the calendar year, some $18.5 billion of total revenue. Obviously, primarily our COVID
Moderna Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 17, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers